Janux plunges 50% as JANX007 trial spurs broad target cuts
Janux Therapeutics sank nearly 50% after analysts cut price targets following new Phase 1 results for its prostate cancer drug JANX007. While the company highlighted strong PSA declines, durable responses, and manageable safety, analysts flagged delays and unanswered questions. Despite the selloff, several firms kept bullish ratings.